A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors

Trial Profile

A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Veliparib (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia; Lymphoma; MALT lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Mar 2017 Results evaluating the safety, tolerability, and efficacy published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 08 Dec 2015 Results (n=15) from Phase 1b and Cohort Expansion part of the study presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top